Annals of Hepatology

Article	Citations
O-1 SEROPREVALENCE AND MOTHER-TO-CHILD TRANSMISSION OF HEPATITIS B AND C VIRUSES AMONG PREGNANT WOMEN IN A MATERNAL AND CHILDREN HOSPITAL FROM THE PROVINCE OF BUENOS AIRES	323
P- 43 HCV TESTING AND TREATMENT IN FOUR BRAZILIANS’ CORRECTIONAL SETTINGS	87
P- 91 CHANGES IN EARLY VISUAL PERCEPTION IN PATIENTS WITH MINIMAL HEPATIC ENCEPHALOPATHY	53
Levels of IGFBP-1, 3 and 7 in human serum induced by alcohol consumption, NAFLD and dual insult	52
P- 16 HEPATOCELLULAR CARCINOMA IN CENTRAL AMERICA: A MULTIDISCIPLINARY APPROACH IN A COSTA RICAN COHORT	50
Association of IFNL3 gene rs4803217 with spontaneous clearance of Hepatitis C virus in patients from West Mexico	40
P-18 PREVALENCE AND EPIDEMIOLOGICAL CHARACTERISTICS OF INFECTIONS IN PATIENTS WITH CHRONIC LIVER DISEASE: RETROSPECTIVE ANALYSIS FROM A GENERAL HOSPITAL IN MONTERREY, NUEVO LEON, MEXICO	35
Short-term efficacy and safety of l-ornithine l-aspartate therapy in patients with cirrhosis and minimal hepatic encephalopathy: a real-life cohort study	34
Progression of intraductal papillary neoplasm of the bile duct (IPNB): A proposed model through the observation of patients with non-resected tumors	33
P-85 USE OF LOW DOSES OF GENERIC TACROLIMUS AND THERAPEUTIC LEVELS IN LIVER TRANSPLANT PATIENTS: RESULTS FROM A SINGLE CENTER IN PERU	32
P-64 THE ALCOHOL-ASSOCIATED LIVER DISEASE PARADOX IN CHILE: AN ASSESSMENT WITH DATA FROM THE NATIONAL HEALTH SURVEY (ENS 2016-2017)	32
O-18 IMPAIRED ANTI-HBV VACCINE RESPONSE IN NON-CIRRHOTIC CHRONIC HCV PATIENTS IS NOT OVERCOME BY DOUBLE DOSE REGIMEN. FOURTH DOSE MAYBE THE ANSWER!	31
P-55 QUALITY OF LIFE IMPROVES IN PATIENTS WITH OR WITHOUT CIRRHOSIS AFTER HEPATITIS C CURE WITH DIRECT-ACTING ANTIVIRAL AGENTS	30
Etiology and find in portal vein thrombosis at the Hospital de Especialidades del Centro Médico Nacional La Raza	28
Examining genetic associations with hepatic steatosis in Mexican-origin adults	27
O2- CHARACTERIZATION OF STEATOTIC LIVER DISEASE AND THE ROLE OF GENETIC BACKGROUND IN LATIN AMERICA	26
P-8 TRENDS IN ALCOHOL-ASSOCIATED CIRRHOSIS IN CHILE: A POPULATION STUDY BETWEEN 2001 TO 2020.	26
P-46 IMMUNOSUPPRESSION IN POST LIVER TRANSPLANTATION: REVIEW OF THE EXPERIENCE IN A CHILEAN UNIVERSITY HOSPITAL	25
Dietary macro and micronutrients associated with MASLD: Analysis of a national US cohort database	24
Targeting cellular senescence as a therapeutic approach in non-alcoholic steatohepatitis	23
Anti-gp210-positive primary biliary cholangitis: The dilemma of clinical treatment and emerging mechanisms	23
Genome-wide DNA methylation and transcriptomic analysis of liver tissues subjected to early ischemia/reperfusion injury upon human liver transplantation	23
“THE EFFECT OF GROWTH DIFFERENTIATION FACTOR 11 (GDF11) ON THE RESPONSE OF TUMOR-ASSOCIATED MACROPHAGES IN HEPATOCELLULAR CARCINOMA DERIVED CELLS”	22
A thorny matter: Spur cell anemia	21
P-110 CHANGES IN THE CLINICAL PRESENTATION OF PRIMARY BILIARY CHOLANGITIS (PBC) OVER THE YEARS IN A UNIVERSITY CENTER IN ARGENTINA	21

Characteristics and in-hospital outcomes of COVID-19 patients with abnormal liver biochemical tests	21
Neutrophil/lymphocyte index as a prognostic predictor in patients with primary biliary cholangitis	20
Skeletal muscle as a source of IGFBP-2 in a murine model of metabolic dysfunction associated with steatotic liver disease.	20
Acute Liver Failure due to Hepatitis A Virus: A Report of Two Cases	20
Characterization and determination of prevalence in autoimmune liver diseases in a tertiary center.	19
Activation of the NLRP3 inflammasome by CCl4 exacerbates hepatopathogenic diet-induced experimental NASH	18
A practical approach to the endoscopic management of biliary strictures after liver transplantation	18
Elevated lactate/albumin ratio as a novel predictor of in-hospital mortality in hospitalized cirrhotics	18
Kasabach-Merritt syndrome in an adult treated by embolization prior to liver transplantation: a case report.	18
Reply to: “correspondence about “Efficacy and safety of basiliximab”	18
Correspondence: “A multisociety Delphi consensus statement on new fatty liver disease nomenclature”	17
Circ-LARP1B knockdown restrains the tumorigenicity and enhances radiosensitivity by regulating miR-578/IGF1R axis in hepatocellular carcinoma	17
P-40 ASSOCIATION BETWEEN LIVER STIFFNESS MEASUREMENTS USING MR ELASTOGRAPHY AND PORTOSYSTEMIC SHUNTS IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE	16
Development of a biodegradable prosthesis through tissue engineering, for the organ-replacement or substitution of the extrahepatic bile duct	16
MiR-20b-5p promotes hepatocellular carcinoma cell proliferation, migration and invasion by down-regulating CPEB3	16
Lipocalin-2 silencing alleviates sepsis-induced liver injury through inhibition of ferroptosis	16
Tumor-associated macrophages contribute to cholangiocarcinoma progression and chemoresistance through activation of ID1	16
Energy metabolism: An emerging therapeutic frontier in liver fibrosis	16
Clinical and microbiological characteristics of bacterial infections in patients with cirrhosis. A prospective cohort study from Argentina and Uruguay	16
Artificial liver support system in pediatric acute liver failure due to mushroom poisoning: Case series	15
Trajectories of patients relisted for liver transplantation	15
TSH and its Correlation in the Development of Fibrosis in Patients with Hypothyroidism in a Tertiary Care Hospital	15
P-65 NEOPORTA WITH OR WITHOUT TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT AS A VIABLE TREATMENT OF CHRONIC PORTAL VEIN THROMBOSIS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS	15
P-19 ASSOCIATION OF TM6SF2 GENE POLYMORPHISMS WITH CARDIOVASCULAR RISK IN PATIENTS WITH METABOLIC DYSFUNCTION–ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN A HISPANIC ADULT POPULATION	15
Comparison of different prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection	15
P-106 DIAGNOSTIC ACCURACY OF SHEAR-WAVE ELASTOGRAPHY IN METABOLIC DYSFUNCTION–ASSOCIATED STEATOTIC LIVER DISEASE, A SINGLE CENTER REPORT	15
Prevalence of fibrosis and steatosis determined by transient elastography and controlled attenuation parameter (Fibroscan®) in diabetic patients	14
IGFBP2: a possible molecular link between liver, heart, and bloodstream during metabolic dysfunction-associated steatotic liver disease	14
OP-4 IMPLEMENTATION OF A RE-LINKAGE TO CARE STRATEGY IN PATIENTS WITH CHRONIC HEPATITIS C WHO WERE LOST TO FOLLOW-UP IN LATIN AMERICA	14
HGF/c-Met regulates p22phox subunit of the NADPH oxidase complex in primary mouse hepatocytes by transcriptional and post-translational mechanisms	14
Ceftriaxone versus cefotaxime in the treatment of spontaneous bacterial peritonitis	14
The Hepatic Effect of Sub-chronic Chronic Cadmium Exposure.	14
An exploratory analysis of patient factors influencing acceptance of extended criteria liver grafts	14
Moringa oleifera decreases biomarkers of oxidative stress in a murine NASH model	14
Liver Injury Induced by Peumus boldus with Fatal Outcome. Case Report	14
Twenty-year follow-up of an outbreak of hepatitis C in a small rural town of Argentina: The O'Brien Project	14
PROFILE OF PRO AND ANTI-INFLAMMATORY CYTOKINES IN PATIENTS WITH CHRONIC LIVER DISEASE IN THE COMPENSATION, INFLAMMATION AND IMMUNOSUPPRESSION PHASES	14
P-123 HEPATOCELLULAR CARCINOMA SURVIVAL: EXPERIENCE OF THE MULTIDISCIPLINARY COMMITTEE AT HOSPITAL ESPECIALIDADES EUGENIO ESPEJO IN QUITO – ECUADOR	14
P-2 DE NOVO LIPOGENESIS MARKERS ARE INVOLVED IN METABOLIC ASSOCIATED FATTY LIVER DISEASE PROGRESSION IN BTBR OB/OB MICE	13
Treatment with nucleoside and nucleotide analogues in patients with chronic hepatitis B virus infection	13
Detection of Hepatitis C and risk factors in the general population of the Centro Médico Nacional La Raza	13
OP-3 HCV MICROELIMINATION PROGRAM IN HEMODIALYSIS PATIENTS: SUCCESS OF A MULTI-STAKEHOLDER PARTNERSHIP BASED ON A NATIONAL ERADICATION STRATEGY	13
PORTA VEIN THROMBOSIS (PVT) IN CIRRHOTIC PATIENTS PRE AND DURING THE PANDEMIC BY SARS-COV2	13
Autoimmune hepatitis with superimposition of primary sclerosing cholangitis on non-specific chronic ulcerative colitis	13
P-114 LIVER TRANSPLANTATION FOR NON-ALCOHOLIC STEATOHEPATITIS: OUTCOMES IN THE MAIN TRANSPLANT CENTER IN PERU	13
P- 26 EFFECT OF PROTEIN X OF THE HEPATITIS B VIRUS AND HEXACHLOROBENZENE ON LIVER CELL GROWTH DYSREGULATION	12
Silymarin is an ally against insulin resistance: A review	12
Introduction of a standardized protocol for cardiac risk assessment in candidates for liver transplant – A retrospective cohort analysis	12
P-13 PREVALENCE, CHARACTERIZATION, AND SURVIVAL OF ACUTE ON CHRONIC LIVER FAILURE IN A LATIN AMERICAN COHORT:  A MULTICENTER STUDY	12
DILI and Dress syndrome secondary to treatment with DoTbal, in a patient with tuberculosis at the rural hospital from Papantla – IMSS Bienestar	12

Deep stool microbiome analysis in cirrhosis reveals an association between short-chain fatty acids and hepatic encephalopathy	12
HEPATOCELLULAR CARCINOMA IN VERACRUZ: A SURVEILLANCE COMPARISON BETWEEN TREATMENTS	12
P-15 MMP-2 AND MMP-9 LEVELS IN ALCOHOLIC LIVER DISEASE, NON-ALCOHOLIC FATTY LIVER DISEASE AND CHRONIC HEPATITIS C	12
Impact of hepatitis B surface antigen quantification on achieving a functional cure in patients with chronic hepatitis B: A systematic review and meta-analysis	12
Gradual dosing of ursodeoxycholic acid in mothers with intrahepatic cholestasis of pregnancy may improve composite neonatal outcome	12
The dual role of HCV protein expression in communication between host cells presents potential applications in the treatment of liver fibrosis	11
Optimal ALT threshold for the automated diagnosis of MASLD: A population-based study using iLFT	11
Mechanisms and therapeutic targets of mitochondria in the progression of metabolic dysfunction-associated steatotic liver disease	11
Epidemiology and natural history of chronic Hepatitis B in the Canadian province of Alberta from 2012 to 2021: A population-based study	11
Glycemic control, the unconsidered outcome in the treatment of nonalcoholic fatty liver disease	10
Characteristics of bacterial infections and prevalence of multidrug-resistant bacteria in hospitalized patients with liver cirrhosis in Germany	10
Stroop test, Quickstroop, and the 1-min animal naming test for minimal hepatic encephalopathy diagnosis: A multicenter study in Mexico	10
Prolonged-release pirfenidone in patients with compensated cirrhosis. Final results of the multicenter study ODISEA, controlled against placebo, plus standardized care_2023	10
IL-18 discriminates highly frequent hepatitis E virus positive from negative blood donors in Mexico	10
Analysis of the impact of fatty acid metabolism on immunotherapy for hepatocellular carcinoma	10
Efficacy and safety of intravenous L-ornithine L-aspartate in patients with grade III and IV hepatic encephalopathy	10
P-81 ALTERNATIVE THERAPIES FOR DIFFICULT-TO-TREAT AUTOIMMUNE HEPATITIS: AN EXPERIENCE OF THREE BRAZILIAN REFERRAL CENTERS	10
Prevalence of liver cirrhosis based on the metabolic health and weight criteria: Report from the Korea National Health and Nutrition Examination Survey (KNHANES) data analysis	10
Cumulative incidence of solid and hematological De novo malignancy after liver transplantation in a multicentre cohort	10
Clues to decipher the origin of severe acute hepatitis in children: a new enigma during the COVID-19 pandemic	10
Evaluation of the MELNa AGIB Scale to Predict Mortality in Patients with Cirrhosis and Variceal Hemorrhage.	10
A data-driven approach to decode metabolic dysfunction-associated steatotic liver disease	10
Jejunal lymphoma of large cell high grade B monomorphic in a patient with hepatic transplant	9
DETERMINATION OF LEUKOCYTE PROFILE IN CHRONIC ALCOHOL CONSUMPTION	9
Identification of resistance mutations to DAA's against Hepatitis C Virus in infected subjects in Mexico	9
P- 18 ANASTROZOLE MAY NOT BE ASSOCIATED FATTY LIVER DISEASE AND HEPATIC FIBROSIS IN WOMEN WITH BREAST CANCER	9
P-80 SEVERELY OBESE PATIENTS HAD HEPATIC FIBROSIS EVEN WITHOUT METABOLIC SYNDROME	9
Evaluation of the early response to empirical treatment and its association with cultures in patients with spontaneous bacterial peritonitis (SBP)	9
Role of tamsulosin in recovery from thioacetamide-induced subchronic liver damage in a Wistar rat model	9
IMPACT OF REFRACTORY ASCITES ON THE SURVIVAL OF PATIENTS WITH CIRRHOSIS	9
P- 107 EPIDEMIOLOGY, CLINICAL AND TISSUE CHARACTERISTICS OF A LARGE COHORT OF NAFLD/NASH FROM SOUTH AMERICA	9
Ras related GTP binding D promotes aerobic glycolysis of hepatocellular carcinoma	8
MAFLD vs. MASLD: Consensus is unlike evidence!	8
Serum Immunoglobulin M levels and neutrophil/lymphocyte index as predictors of treatment response in patients with primary biliary cholangitis	8
O-11 THE PUBLIC HEALTH POLICIES REDUCE THE LONG-TERM BURDEN OF ALCOHOL-ASSOCIATED LIVER DISEASE WORLDWIDE: DEVELOPMENT OF A PREPAREDNESS INDEX	8
Editorial board	8
P-41 MICRORNAs FROM EVs AS POTENTIAL LIVER FIBROSIS NON-INVASIVE BIOMARKERS IN CHRONIC HEPATITIS C	8
EDITORIAL BOARD	8
O-13 SUB-OPTIMAL GLOBAL PUBLIC HEALTH POLICIES AND STRATEGIES TO TACKLE HEPATOCELLULAR CARCINOMA	8
EDITORIAL BOARD	8
P-4 RISK OF HCC IN SOUTH AMERICANS ASSOCIATED WITH TLL1 VARIANT SINGLE NUCLEOTIDE POLYMORPHISM	8
Hepatic histologic findings in a murine model of diet induced-steatotic liver disease and acute alcohol intake	8
COVID-19 vaccine-induced immune thrombotic thrombocytopenia: An emerging cause of splanchnic vein thrombosis	8
OP-1 FEATURES OF IDIOSYNCRATIC DRUG-INDUCED LIVER INJURY (DILI) IN LATIN AMERICA: LONG-TERM EXPERIENCE OF THE LATINDILI NETWORK	8
Autoimmune hemolytic anemia as a paraneoplastic syndrome in hepatocarcinoma, case report	8
HEPATOCELLULAR CARCINOMA: CLINICAL AND EPIDEMIOLOGICAL FEATURES IN VERACRUZ	7
P-36 ACCURACY OF PROGNOSTIC SCORES IN PREDICTION OF MORTALITY IN CIRRHOTIC PATIENTS ADMITTED TO THE INTENSIVE CARE UNIT	7
P-87 TRANSCULTURAL ADAPTATION OF THE MEDITERRANEAN DIET TO THE DIETARY HABITS OF EACH GEOGRAPHICAL REGION OF ARGENTINA FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MA	7
P-14 SPONTANEOUS BACTERIAL PERITONITIS IN CIRRHOTIC PATIENTS: PREVALENCE AND ANTIBIOTIC RESISTANCE PATTERNS	7
P-49 COVID 19-PANDEMIC AND OUTCOMES IN DECOMPENSATE CIRRHOSIS-10 MONTHS REVIEW	7
P-120 NATIONAL SURVEY ON CURRENT PRACTICES TO PREVENT HBV REACTIVATION DURING IMMUNOSUPPRESSION	7
Regulation of TGF-β1, 2, and 3 and IL-10 at systemic level in chronic liver disease	7
P-104 IMPACT OF BACTERIAL INFECTIONS IN THE CLINICAL COURSE OF CIRRHOTIC PATIENTS ADMITTED TO THE INTENSIVE CARE UNIT	7
Aminotransferases disorders associated with venous thromboembolic events in patients infected with COVID-19	7
Endohepatology: current status and perspectives	7
The presence of diabetes impacts liver fibrosis and steatosis by transient elastography in a primary care population	7
P-1 PREVALENCE AND EPIDEMOLOGY OF BACTERIAL INFECTIONS IN PATIENTS WITH ALCOHOLIC HEPATITIS: A RETROSPECTIVE STUDY OF PATIENTS ADMITTED AT THE SAN RAFAEL DE ALAHUELA HOSPITAL, COSTA RICA	7
EDITORIAL BOARD	7
P-37 EXPERIENCE IN MEXICO WITH DIRECT ACTING ANTIVIRALS AS A TREATMENT FOR HEPATITIS C	7
P-45 LIVER HEMODYNAMIC AND TRANSJUGULAR LIVER BIOPSY: ROLE IN DIAGNOSTIC AND THERAPEUTIC BEHAVIOR	7
P-44 LONG-TERM SURVIVAL IN PATIENTS WITH LIVER TRANSPLANTATION	7
Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis	7
P-82 URSODEOXYCHOLIC ACID AND/OR CIPROFIBRATE FOR TREATING PATIENTS WITH PRESUMPTIVE DIAGNOSIS OF LOW PHOSPHOLIPID CHOLELITHIASIS, A CLINICAL SPECTRUM OF PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS	7
Platelets level variability during the first year after liver transplantation in the risk prediction model for recipients mortality	7
P-15 WAITING LIST FOR LIVER TRANSPLANTATIOS: CLINICAL AND ECONOMIC BURDEN, RETROSPECTIVE STUDY	7
Prevalence of non-alcoholic fatty liver disease and liver fibrosis in a general population cohort from Argentina	6
Liver cirrhosis is a risk factor for poor prognosis of acute cholangitis caused by choledocholithiasis	6
Validation of the Hepamet fibrosis score in a multi-ethnic Asian population	6
Metabolic dysfunction: The silenced connection with fatty liver disease	6
The influence of hepatitis C virus eradication on hepatocarcinogenesis in patients with hemophilia	6
P-124 POST PARACENTESIS COMPLICATIONS IN PATIENTS WITH DIAGNOSIS OF LIVER CIRRHOSIS	6
EDITORIAL BOARD	6
TCD assessment in fulminant hepatic failure: Improvements in cerebral autoregulation after liver transplantation	6
Comparison of surgical resection and transcatheter arterial chemoembolization for large hepatocellular carcinoma: a systematic review and meta-analysis	6
Radiofrequency ablation and percutaneous ethanol injection versus radiofrequency ablation alone for hepatocellular carcinoma: a systematic review and meta-analysis	6
P-62 INFECTIONS IN THE FIRST MONTH POST LIVER TRANSPLANTATION IN A TRANSPLANT CENTER IN CHILE	6
Efficacy of blood plasma spectroscopy for early liver cancer diagnostics in obese patients	6
Differential effect of the allele G ADRB2 (rs1042714) and allele C ADRB3 (rs4994) and its association with metabolic-associated steatotic liver disease (MASLD) risk factors in Mexican population.	6
Helicobacter pylori cagA/vacAs1-m1 strain is associated with high risk of fibrosis in metabolic-dysfunction-associated steatotic liver disease	6
Outcomes and risk factors for mortality in clostridioides difficile infection in patients with NAFLD and NASH	6

Overall and subgroup prevalence of non-alcoholic fatty liver disease and prevalence of advanced fibrosis in the United States: An updated national estimate in National Health and Nutrition Examination	6
P-122 LIVER TRANSIENT ELASTOGRAPHY (FIBROSCAN). FIRST REPORT OF EXPERIENCE IN ECUADOR	6
P- 42 METABOLIC ASSOCIATED FATTY LIVER DISEASE AND BODY COMPOSITION MEASUREMENT	5
Interpretive bias on research evidence: Striving to meet the trustworthiness criteria	5
O-14 NON-ALCOHOLIC FATTY LIVER DISEASE IS INFLUENCED BY THE INTERACTION OF HELICOBACTER PYLORI INFECTION AND G-ALLELE OF PNPLA3	5
Clinical characteristics of liver injury in SARS-CoV-2 Omicron variant- and Omicron subvariant-infected patients	5
From NAFLD to MASLD: Promise and pitfalls of a new definition	5
P-75 INFLUENCE OF THE ARTERIAL HEPATIC FLOW IN ELASTOGRAPHY (2D SHEARWAVE) LIVER VALUES	5
P-121 SEPTIC SHOCK IN LIVER CIRRHOSIS: A COHORT STUDY OF A UNIVERSITY HOSPITAL IN CHILE	5
Management of hepatocellular carcinoma recurrence after liver transplantation	5
Non-alcoholic fatty liver disease is associated with greater risk of 30-day hospital readmission in the United States (U.S.)	5
Hepatocellular carcinoma and upper gastrointestinal bleeding	5
Risk factors for sarcopenia in cirrhotic patients under evaluation for liver transplantation.	5
P- 54 HEPATITIS C MICROELIMINATION IN FORMER DRUG USERS	5
Circular RNA hsa_circ_0098181 inhibits metastasis in hepatocellular carcinoma by activating the Hippo signaling pathway via interaction with eEF2	5
O-26 ASPARTATE AMINOTRANSFERASE, AGE AND D-DIMER IN COVID-19 PATIENTS: A USEFUL PROGNOSTIC MODEL	5
Diethylnitrosamine and 2-acetylaminofluorene chronic administration leads to biochemical and histologic changes related to hepatocellular carcinoma in Wistar rats	5
SARS-CoV-2 vaccination in liver transplant recipients: We still haven't found what we are looking for	5
Daytime napping and risk of liver cancer: A large population-based prospective cohort study	5
Short-term response of p300 evoked potential in patients with minimal hepatic encephalopathy treated with l-ornithine, l-aspartate	5
Trends in drug prescriptions for type 2 diabetes, hypertension, and dyslipidemia among adults with non-alcoholic fatty liver disease	5
Evaluation of the hepatoprotective effect of Flourensia cernua against the damage induced ischemia-reperfusion in Wistar rats.	5
Most Common Complications in Patients Post Liver Transplantation at a Hospital in Mexico.	5
Hepatitis C virus NS5A and core proteins regulate epithelial-mesenchymal transition biomarkers in hepatoma cells	5
Good post-transplant outcomes using liver donors after circulatory death when applying strict selection criteria: a propensity-score matched-cohort study	5
P-23 SEROLOGICAL PROFILE OF HEPATITIS B AND C IN REUMATHOLOGIC PATIENTS IN USE OF IMMUNOSSUPRESSIVE THERAPY	5
CORRELATION BETWEEN SARCOPENIA AND HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS	5
OP-5 ACUTE-ON-CHRONIC LIVER FAILURE (ACLF) CRITERIA IN ALCOHOL-ASSOCIATED HEPATITIS: IMPLICATIONS FOR LIVER TRANSPLANTATION	5
Outcomes of liver transplantation in patients 70 years or older: a systematic review and meta-analysis	5
OP-13 CHOLANGIOCARCINOMA IN LATIN AMERICA: A MULTICENTER OBSERVATIONAL STUDY ALERTS ON ETHNICAL DISPARITIES IN TUMOR PRESENTATION AND OUTCOME	4
Efficacy of prophylactic antibiotics in the adjuvant treatment of alcohol-related liver disease (ALD): A systematic review and meta-analysisProphylactic antibiotics in ALD	4
Editorial board	4
P-65 CONCORDANCE OF FIB-4 WITH TRANSITION ELASTOGRAPHY IN THE DIAGNOSIS OF ADVANCED LIVER FIBROSIS	4
P-6 SOFOSBUVIR CONTAINING REGIMENS ARE SAFE AND EFFECTIVE IN ADOLESCENTS WITH CHRONIC HEPATITIS C INFECTION	4
P- 73 ULTRASOUND VISUALIZATION OF THE LIVER	4
Evaluation of the ALBI, MELD, MELD-Na, MELD 3.0 score in patients with hepatocellular carcinoma treated with Yttrium-90 (90y)	4
Hepatoprotective effects of N-acetylcysteine prevents hepatocellular carcinoma development induced experimentally.	4
Clinical efficacy and safety of external radiotherapy combined with sorafenib in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis	4
P-7 EPIDEMIOLOGY OF AUTOIMMUNE HEPATITIS IN LATIN AMERICA: PRELIMINARY RESULTS FROM ALLATIN COHORT	4
Predictive role of microvesicles in cirrhotic patients: A promised land or a land of confusion? A narrative review	4
One-step diagnosis strategy together with multidisciplinary telematics referral perform an effective approach for identifying and treating patients with active Hepatitis C infection	4
EDITORIAL BOARD	4
P-121 CORRELATION BETWEEN HEPATOPULMONARY SYNDROME AND OXYGEN SATURATION PULSE OXIMETRY IN CIRRHOTIC PATIENTS	4
CLIF-C-ACLF scale to predict mortality in pediatric patients with acute-on-chronic liver failure	4
P- 39 N-ACETYL CYSTEINE ATTENUATES ALTERATIONS GENERATED IN EXPERIMENTAL LIVER STEATOSIS INDUCED BY CHRONIC ALCOHOL CONSUMPTION PLUS A HYPERCALORIC DIET	4
Roles of diencephalon/mesencephalon homeobox 1 in the development and prognosis of hepatocellular carcinoma	4
P-77 TRIPLE THERAPY FOR DIFFICULT-TO-TREAT PRIMARY BILIARY CHOLANGITIS: A SYSTEMATIC REVIEW AND SINGLE-ARM META-ANALYSIS	4
Clinical spectrum and long-term outcomes of non-cirrhotic portal venous system thrombosis in Hispanic population	4
P-55 FIRST EVALUATION ALBI SCORE COULD BE A TOOL FOR RISK STRATIFICATION OF HCC DEVELOPMENT IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS	4
P- 24 RISK OF MULTIPLE DRUG INTERACTIONS POTENTIALLY LINKED TO SAFETY IN PATIENTS RECEIVING PANGENOTYPIC DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C	4
O-11 ENHANCEMENT OF F4/80+CD11B-CD206+ KUPFFER CELLS IN LIVER TISSUE: EFFECT OF MARESIN-1 AS HEPATOPROTECTIVE AGENT	4
CLINICAL, BIOCHEMICAL, AND IMAGE CHARACTERISTICS IN PATIENTS WITH A DIAGNOSIS OF AMEBIC AND BACTERIAL LIVER ABSCESS.	4
Evaluation of the hypolipidemic effect of cinnamon essential oil in a model of acute damage induced by triton WR-1339	4
O-3 DEVELOPMENT OF LENTIVIRAL VECTORS FOR INHIBITION OF HEPATITIS B VIRUS VIA SMALL INTERFERING RNA	3
An Acknowledgement	3
Examining the prevalence of hepatic steatosis and advanced fibrosis using non-invasive measures across Canada: A national estimate using the Canadian Health Measures Survey (CHMS) from 2009-2019	3
EncephalApp Stroop Test validation for the screening of minimal hepatic encephalopathy in Brazil	3
Nomogram for prediction of long-term survival with hepatocellular carcinoma based on NK cell counts	3
Sarcopenia in patients with liver cirrhosis according to hepatic functional reserve	3
Editorial Board	3
O-25 ASSESSMENT OF MODELS FOR PREDICTING RESPONSE TO CORTICOIDS TREATMENT IN ALCOHOL-ASSOCIATED HEPATITIS: A GLOBAL COHORT STUDY	3
Body mass index and diabetes predict severity of liver fibrosis across the spectrum of steatotic liver disease	3
Ethanol with thioacetamide murine model of alcoholic liver disease identifies hepatic pathways as targets for the human disease	3
P-49 CONCENTRATION OF IL-12 AND CXCL-10 IN CHRONIC LIVER DISEASES	3
P-27 DESCRIPTIVE STUDY ON PATIENTS WITH HEPATOCARCINOMA IN A PUBLIC HOSPITAL 2018-2023	3
P- 56 TUBERCULOSIS IN LIVER TRANSPLANT RECIPIENTS: EXPERIENCE OF A SINGLE CENTER	3
MCM3 promotes hepatocellular carcinoma progression via Epithelial-mesenchymal Transition through AKT/Twist signaling pathway	3
Alcoholic cirrhosis-associated immune dysfunction: What does it imply for us?	3
Portal cholangiopathy secondary to cavernomatous transformation of the portal vein. Case report	3
Sarcopenia as a predictor of risk of minimal hepatic encephalopathy in patients with liver cirrhosis	3
Influence of socioeconomic factors on liver transplant survival outcomes in patients with autoimmune liver disease in the United States	3
O-2 CHARACTERIZATION OF SERUM LEVELS OF BILE ACIDS, EXTRACELLULAR VESICLES AND ITS CARGO IN ALCOHOL-ASSOCIATED LIVER DISEASE	3
P-68 FREQUENCY AND FACTORS ASSOCIATED WITH ANTIBIOTIC DE-ESCALATION IN PATIENTS WITH CIRRHOSIS AND BACTERIAL INFECTIONS	3
Clinical characteristics, therapeutic approach, and outcomes in patients with hepatocellular carcinoma at a third-level hospital.	3
P- 39 CLINICAL SIGNIFICANCE OF GRADE 1 HEPATIC ENCEPHALOPATHY IN PATIENTS HOSPITALIZED FOR COMPLICATIONS OF CIRRHOSIS	3
Colorimetric test for early diagnosis of spontaneous bacterial peritonitis.	3
The changing impact of pre-liver transplant renal dysfunction on post-transplant survival: results of 2 decades from a single center	3
O-17 NUTRICIONAL AND PHYSICAL THERAPHY IMPROVES LIVER FRAILTY INDEX IN LISTED PATIENTS WITH CIRRHOSIS: RANDOMIZED CONTROLLED TRIAL. INTERIM ANALYSIS	3
NAFLD VS MAFLD. The evidence-based debate has come. Time to change?	3
Prevalence and evaluation of sleep disturbances in Mexican patients with hepatic cirrhosis through the application of the Pittsburgh sleep questionnaire	3
Cavin1 activates the Wnt/β-catenin pathway to influence the proliferation and migration of hepatocellular carcinoma	3
O-37 AMOXICILLIN-CLAVULANATE INDUCED LIVER INJURY: TEN YEARS EXPERIENCE FROM LATINDILI REGISTRY.	3
Development and external validation of a machine-learning based model to predict pre-sarcopenia in MASLD population: Results from NHANES 2017–2018	3
Clinically significant portal hypertension in patients with primary biliary cholangitis: Clinicopathological features and prognostic value	3
Pirfenidone decreases insulin, glucagon, leptin, plasminogen activator inhibitor 1, preventing nonalcoholic steatohepatitis and myocarditis in an obesity moldel	3
P- 48 EFFECT OF THE COMBINATION OF ORLISTAT AND L-CARNITINE ON THE QUALITY OF LIFE (SF.36) IN 16 OVERWEIGTH PATIENTS	3
P-84 HAVE CFTR MODULATORS CHANGED THE NEED FOR LIVER TRANSPLANTATION AMONG PATIENTS WITH CYSTIC FIBROSIS? AN ANALYSIS OF THE UNOS DATABASE	2
P-76 PROGNOSTIC FACTORS FOR SEVERITY AND MORTALITY IN COVID-19: ARE LIVER TESTS IMPORTANT?	2
Integrated analyses and a novel nomogram for the prediction of significant fibrosis in patients	2
P-97 THE ROLE OF PSYCHOLOGICAL STRESS IN METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE. A PILOT STUDY	2
P-39 EXPERIENCE IN THE MANAGEMENT OF REFRACTORY HEPATIC ENCEPHALOPATHY THROUGH ENDOVASCULAR THERAPY	2
P-124 ASSOCIATED FACTORS WITH CLINICAL COURSE OF VASCULAR LIVER DISEASE IN A PUBLIC HOSPITAL IN PERU	2
EDITORIAL BOARD	2
P-27 OBESITY AND LIVER STEATOSIS IN ADOLESCENTS AND YOUNG ADULTS - RELATED FACTORS AND THE IMPACT OF LIFESTYLE	2
OP-5 ALCOHOL-ASSOCIATED HEPATITIS IN LATIN AMERICA: RESULTS FROM THE AH-LATIN STUDY	2